rs863224974
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_000166.6(GJB1):c.44G>A(p.Arg15Gln) variant causes a missense change. The variant allele was found at a frequency of 0.000000912 in 1,096,733 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 22)
Exomes 𝑓: 9.1e-7 ( 0 hom. 0 hem. )
Consequence
GJB1
NM_000166.6 missense
NM_000166.6 missense
Scores
7
4
6
Clinical Significance
Conservation
PhyloP100: 3.83
Genes affected
GJB1 (HGNC:4283): (gap junction protein beta 1) This gene encodes a member of the gap junction protein family. The gap junction proteins are membrane-spanning proteins that assemble to form gap junction channels that facilitate the transfer of ions and small molecules between cells. According to sequence similarities at the nucleotide and amino acid levels, the gap junction proteins are divided into two categories, alpha and beta. Mutations in this gene cause X-linked Charcot-Marie-Tooth disease, an inherited peripheral neuropathy. Alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Oct 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PM1
In a chain Gap junction beta-1 protein (size 282) in uniprot entity CXB1_HUMAN there are 4 pathogenic changes around while only 0 benign (100%) in NM_000166.6
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.946
PP5
Variant X-71223751-G-A is Pathogenic according to our data. Variant chrX-71223751-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 217169.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-71223751-G-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GJB1 | NM_000166.6 | c.44G>A | p.Arg15Gln | missense_variant | 2/2 | ENST00000361726.7 | NP_000157.1 | |
GJB1 | NM_001097642.3 | c.44G>A | p.Arg15Gln | missense_variant | 2/2 | NP_001091111.1 | ||
GJB1 | XM_011530907.3 | c.44G>A | p.Arg15Gln | missense_variant | 2/2 | XP_011529209.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GJB1 | ENST00000361726.7 | c.44G>A | p.Arg15Gln | missense_variant | 2/2 | 1 | NM_000166.6 | ENSP00000354900 | P1 |
Frequencies
GnomAD3 genomes Cov.: 22
GnomAD3 genomes
Cov.:
22
GnomAD4 exome AF: 9.12e-7 AC: 1AN: 1096733Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 362117
GnomAD4 exome
AF:
AC:
1
AN:
1096733
Hom.:
Cov.:
31
AF XY:
AC XY:
0
AN XY:
362117
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 22
GnomAD4 genome
Cov.:
22
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jul 11, 2022 | This variant has been identified in multiple unrelated individuals with clinical features associated with this gene and appears to segregate with disease in at least one family. This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). At least one other missense variant at this codon is considered to be pathogenic or likely pathogenic, suggesting this variant may also cause disease. Computational tools predict that this variant is damaging. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 21, 2022 | Published functional studies demonstrate no affect on the expression and localization of the protein, but do show a moderate effect of the channel conductance (Shy et al., 2007; Deschenes et al., 1997; Abrams et al., 2001); The majority of missense variants in this gene are considered pathogenic; Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 9364054, 28448691, 19062535, 15006706, 28768847, 17353473, 11325342, 22159091, 10586261, 27098783, 28286897, 31827005, 32010055, 11718056, 32376792, 8162049) - |
Charcot-Marie-Tooth disease X-linked dominant 1 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | May 22, 2023 | The GJB1 c.44G>A variant is classified a PATHOGENIC variant (PS4, PS3_moderate, PM2, PM5_supporting, PP3) The variant is a single nucleotide change in exon 2/2 of the GJB1 gene, which is predicted to change the amino acid arginine at position 15 in the protein to glutamine. The variant is in dbSNP (rs863224974) but is absent from population databases (PM2). The variant has been reported multiple times in unrelated individuals with clinical phenotype of CMT (PMID:8162049, 28286897, 32010055) (PS4). Functional studies have demonstrated that the variant has no effect on protein localization and channel formation but does show moderate effect on channel conductance (PMID: 9364054, 11325342, 15006706) (PS3_moderate). Other missense changes at the same amino acid residue have been previously reported and classified as pathogenic/ like pathogenic (i.e. p.R15W, p.R15P) (PM5_supporting). This variant has been reported in ClinVar (Variation ID: 217169) or HGMD (Accession no.: CM940828) as Pathogenic/ disease causing. Computational predictions support a deleterious effect on the gene or gene product (PP3). - |
Pathogenic, criteria provided, single submitter | clinical testing | Human Genetics Bochum, Ruhr University Bochum | Jul 27, 2023 | ACMG criteria used to clasify this variant: PS3, PP3_STR, PM1, PM2_SUP - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 09, 2020 | The p.R15Q variant (also known as c.44G>A), located in coding exon 1 of the GJB1 gene, results from a G to A substitution at nucleotide position 44. The arginine at codon 15 is replaced by glutamine, an amino acid with highly similar properties. This variant has been frequently reported in individuals with features consistent with X-linked Charcot-Marie-Tooth disease type 1 and has been shown to co-segregate with disease (Capasso M et al. Clin Neurophysiol, 2004 Jan;115:64-70; Fairweather N et al. Hum Mol Genet, 1994 Jan;3:29-34; Sun B et al. Chin Med J (Engl), 2016 May;129:1011-6; Niu J et al. Front Neurol, 2019 Jan;10:1406). Functional studies of this variant have demonstrated proper protein localization and channel formation but some altered channel activity (Deschênes SM et al. J Neurosci, 1997 Dec;17:9077-84; Abrams CK et al. Brain Res, 2001 May;900:9-25; Wang HL et al. Neurobiol Dis, 2004 Mar;15:361-70). Another alteration at this position (p.R15W) has also been reported in multiple patients with features of Charcot-Marie-Tooth disease (Wicklein EM et al. J Neurol Neurosurg Psychiatry, 1997 Sep;63:379-81; Senderek J et al. J Neurol Sci, 1999 Aug;167:90-101). The p.R15Q (c.44G>A) variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Charcot-Marie-Tooth Neuropathy X Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 09, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 15 of the GJB1 protein (p.Arg15Gln). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with CMT (PMID: 8162049, 10586261, 11718056, 14706470, 15719046, 17353473, 18379723, 19062535, 22464564). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 217169). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GJB1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects GJB1 function (PMID: 9364054, 11325342, 15006706). This variant disrupts the p.Arg15 amino acid residue in GJB1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9328258, 10093067, 10639608, 11325342, 24078732). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Pathogenic
DEOGEN2
Uncertain
D;D;D;D;T;.;D
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;.;.;.;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Benign
N;N;N;N;.;.;N
MutationTaster
Benign
D;D;D
PrimateAI
Uncertain
T
PROVEAN
Benign
N;.;N;.;N;.;N
REVEL
Pathogenic
Sift
Benign
T;.;T;.;T;.;T
Sift4G
Benign
T;.;T;.;T;.;T
Polyphen
D;D;D;D;.;.;D
Vest4
MutPred
Loss of MoRF binding (P = 0.0174);Loss of MoRF binding (P = 0.0174);Loss of MoRF binding (P = 0.0174);Loss of MoRF binding (P = 0.0174);Loss of MoRF binding (P = 0.0174);Loss of MoRF binding (P = 0.0174);Loss of MoRF binding (P = 0.0174);
MVP
MPC
1.8
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at